menu

Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments

  • Overview

    Evidence supports the notion that adding targeted agents that have a different mechanism of action than those that cause estrogen receptor interference can improve the benefits and outcomes seen with endocrine therapies alone in HR+/HER2- metastatic breast cancer (mBC). Clinical trial and real-world evidence show that CDK 4/6 inhibitors are safe and effective treatments for HR+/HER2- mBC. Real-world evidence can supplement clinical trial evidence and be more applicable to relevant community-based populations and clinical practice settings.

    Optimal care of mBC involves the use of effective therapies that are supported by the latest evidence and guidelines, selected through a shared decision-making process, and individualized to each patient’s needs. The educational Oncology Clinic features an up-to-date review of real-world evidence surrounding CDK 4/6 inhibitors in mBC that expands on available clinical trial evidence. Through case vignettes that model best practices in shared decision-making, expert faculty will demonstrate how to translate clinical trial and real-world evidence into discussions with patients.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Richard Finn, MD, reported a financial interest/relationship or affiliation in the form of Speaker: Genentech, Inc. Research grant to UCLA: Bayer HealthCare Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; Pfizer Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and Roche/Genentech. Consultant: AstraZeneca Pharmaceuticals LP; Bayer Pharmaceuticals Corporation; CStone Pharmaceuticals; Eisai Inc.; Exelixis, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Pfizer Inc.; Roche/Genentech; and Hengrui. Contracted research funds paid to UCLA: Bayer HealthCare Pharmaceuticals; Eisai Inc.; Exelixis, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Pfizer Inc.; Roche/Genentech; and Hengrui. Contracted research funds paid to UCLA: Bayer HealthCare Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; Pfizer Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and Roche/Genentech.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda  Gracie-King, MS; Jocelyn Timko, BS; Laura Healy, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Melissa Duffy, PA-C hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This activity is designed for medical oncologists, surgical oncologists, and healthcare professionals involved in the therapeutic management of patients with HR+/HER2- mBC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Summarize real-world evidence that supplements clinical trial evidence surrounding the benefits and risks of CDK 4/6 inhibitors in mBC.
    2. Analyze real-world data along with clinical trial data associated with the use of CDK 4/6 inhibitors for mBC with consideration of study design, validity, and implications related to daily practice.
    3. Select optimal CDK 4/6 inhibitor therapy for patients with mBC using team-based collaboration and a shared decision-making discussion with the patient.

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Related

  • Healthcare Image

    Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making Transcript

    Show more
  • ReachMD Healthcare Image

    Getting on Board With Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: A Patient/Clinician Shared Decision-Making Guide

    Show more

Facebook Comments

Recommended
Details
Presenters
Related
Comments

Recommended

  • Overview

    Evidence supports the notion that adding targeted agents that have a different mechanism of action than those that cause estrogen receptor interference can improve the benefits and outcomes seen with endocrine therapies alone in HR+/HER2- metastatic breast cancer (mBC). Clinical trial and real-world evidence show that CDK 4/6 inhibitors are safe and effective treatments for HR+/HER2- mBC. Real-world evidence can supplement clinical trial evidence and be more applicable to relevant community-based populations and clinical practice settings.

    Optimal care of mBC involves the use of effective therapies that are supported by the latest evidence and guidelines, selected through a shared decision-making process, and individualized to each patient’s needs. The educational Oncology Clinic features an up-to-date review of real-world evidence surrounding CDK 4/6 inhibitors in mBC that expands on available clinical trial evidence. Through case vignettes that model best practices in shared decision-making, expert faculty will demonstrate how to translate clinical trial and real-world evidence into discussions with patients.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Richard Finn, MD, reported a financial interest/relationship or affiliation in the form of Speaker: Genentech, Inc. Research grant to UCLA: Bayer HealthCare Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; Pfizer Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and Roche/Genentech. Consultant: AstraZeneca Pharmaceuticals LP; Bayer Pharmaceuticals Corporation; CStone Pharmaceuticals; Eisai Inc.; Exelixis, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Pfizer Inc.; Roche/Genentech; and Hengrui. Contracted research funds paid to UCLA: Bayer HealthCare Pharmaceuticals; Eisai Inc.; Exelixis, Inc.; Eli Lilly and Company; Merck & Co., Inc.; Pfizer Inc.; Roche/Genentech; and Hengrui. Contracted research funds paid to UCLA: Bayer HealthCare Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; Pfizer Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and Roche/Genentech.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda  Gracie-King, MS; Jocelyn Timko, BS; Laura Healy, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Melissa Duffy, PA-C hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This activity is designed for medical oncologists, surgical oncologists, and healthcare professionals involved in the therapeutic management of patients with HR+/HER2- mBC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Summarize real-world evidence that supplements clinical trial evidence surrounding the benefits and risks of CDK 4/6 inhibitors in mBC.
    2. Analyze real-world data along with clinical trial data associated with the use of CDK 4/6 inhibitors for mBC with consideration of study design, validity, and implications related to daily practice.
    3. Select optimal CDK 4/6 inhibitor therapy for patients with mBC using team-based collaboration and a shared decision-making discussion with the patient.

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Related

  • Healthcare Image

    Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making Transcript

    Show more
  • ReachMD Healthcare Image

    Getting on Board With Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: A Patient/Clinician Shared Decision-Making Guide

    Show more

Facebook Comments

Schedule9 Jun 2023
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended